Short-term exposure of umbilical cord blood CD34+ cells to granulocyte-macrophage colony-stimulating factor early in culture improves ex vivo expansion of neutrophils

Cytotherapy

Volumn 13, Issue 3, 2011, Pages 366-377

  Marturana, Flavia ^a   Timmins, Nicholas E ^a   Nielsen, Lars K ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cellular therapy; cytokines; hematopoietic stem cells; neutropenia; neutrophils

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; BLOOD CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UMBILICAL CORD BLOOD;

EID: 79951685102     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.518610     Document Type: Article

References (64)

1. Ziglam HM, Gelly K, Olver W. A survey of the management of neutropenic fever in oncology units in the UK. Int J Antimicrob Agents. 2007;29:430-3. (Pubitemid 46357610)
2. Vamvakas EC, Pineda AA. Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apher. 1996;11:1-9. (Pubitemid 26137441)
3. Ofran Y, Avivi I, Oliven A, Oren I, Zuckerman T, Bonstein L, et al. Granulocyte transfusions for neutropenic patients with life-threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions. Vox Sang. 2007;93:363-9. (Pubitemid 350135080)
4. Price TH, Bowden RA, Boeckh M, Bux J, Nelson K, Liles WC, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95:3302-9. (Pubitemid 30428457)
5. Kerr JP, Liakopolou E, Brown J, Cornish JM, Fleming D, Massey E, et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol. 2003;123: 114-8. (Pubitemid 37222767)
6. Oza A, Hallemeier C, Goodnough L, Khoury H, Shenoy S, Devine S, et al. Granulocyte-colony-stimulating factormobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion. 2006;46:14-23. (Pubitemid 43381780)
7. Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apher. 1997;12:74-81. (Pubitemid 27332727)
8. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood. 1992;80:1405-12.
9. Prince HM, Simmons PJ, Whitty G, Wall DP, Barber L, Toner GC, et al. Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells. Br J Haematol. 2004;126:536-45. (Pubitemid 39093096)
10. Reiffers J, Cailliot C, Dazey B, Attal M, Caraux J, Boiron JM. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet. 1999;354:1092-3. (Pubitemid 29452824)
11. McNiece I, Jones R, Cagnoni P, Bearman S, Nieto Y, Shpall EJ. Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. Hematol Cell Ther. 1999; 41:82-6. (Pubitemid 29170516)
12. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood. 2000;96:2385-90.
13. McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W, et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood. 2000;96: 3001-7.
14. Reichle A, Zaiss M, Rothe G, Schmitz G, Andreesen R. Autologous tandem transplantation: almost complete reduction of neutropenic fever following the second transplantation by ex vivo expanded autologous myeloid postprogenitor cells. Bone Marrow Transplant. 2003;32:299-305. (Pubitemid 36927082)
15. Timmins NE, Palfreyman E, Marturana F, Dietmair S, Luikenga S, Lopez G, et al. Clinical scale ex vivo manufacture of neutrophils from hematopoietic progenitor cells. Biotechnol Bioeng. 2009;104:832-40.
16. Madlambayan GJ, Rogers I, Purpura KA, Ito C, Yu M, Kirouac D, et al. Clinically relevant expansion of hematopoietic stem cells with conserved function in a single-use, closedsystem bioprocess. Biol Blood Marrow Transplant. 2006;12: 1020-30.
17. Madlambayan GJ, Rogers I, Kirouac DC, Yamanaka N, Mazurier F, Doedens M, et al. Dynamic changes in cellular and microenvironmental composition can be controlled to elicit in vitro human hematopoietic stem cell expansion. Exp Hematol. 2005;33:1229-39. (Pubitemid 41416972)
18. Haylock DN, Horsfall MJ, Dowse TL, Ramshaw HS, Niutta S, Protopsaltis S, et al. Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 LIGAND. Blood. 1997;90:2260-72. (Pubitemid 27392710)
19. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood. 1997;89:2644-53. (Pubitemid 27172548)
20. Luens KM, Travis MA, Chen BP, Hill BL, Scollay R, Murray LJ. Thrombopoietin, kit ligand, and fl k2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34(+)Thy-1(+)Lin(-) cells with preserved ability to engraft SCID-hu bone. Blood. 1998;91: 1206-15. (Pubitemid 28086873)
21. Piacibello W, Sanavio F, Severino A, Dane A, Gammaitoni L, Fagioli F, et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood. 1999;93: 3736-49. (Pubitemid 29249820)
22. Qiu LG, Meagher R, Welhausen S, Heye M, Brown R, Herzig RH. Ex vivo expansion of CD34(+) umbilical cord blood cells in a defi ned serum-free medium (QBSF-60) with early effect cytokines. J Hematother Stem Cell Res. 1999;8:609-18. (Pubitemid 30041243)
23. Kusadasi N, van Soest PL, Mayen AE, Koevoet JLM, Ploemacher RE. Successful short-term ex vivo expansion of NOD/SCID repopulating ability and CAFC week 6 from umbilical cord blood. Leukemia. 2000;14:1944-53.
24. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science. 1997;276:1696-9. (Pubitemid 27421976)
25. Madlambayan GJ, Rogers I, Purpura KA, Ito C, Yu M, Kirouac D, et al. Clinically relevant expansion of hematopoi- etic stem cells with conserved function in a single-use, closedsystem bioprocess. Biol Blood Marrow Transplant. 2006;12: 1020-30.
26. Fung YL, Pitcher LA, Willett JE, Reed C, Mison L, Bux J, et al. Alloimmune neonatal neutropenia linked to anti-HNA-4a. Transfus Med. 2003;13:49-52. (Pubitemid 36237097)
27. Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. FLT3 ligand (FL) is a potent inducer of proliferation of highly quiescent human bone marrow CD34+ CD38-cells. Blood. 1995;86:1677.
28. Shah AJ, Smogorzewska EM, Hannum C, Crooks GM. Flt3 ligand induces proliferation of quiescent human bone marrow CD34(+)CD38(-) cells and maintains progenitor cells in vitro. Blood. 1996;87:3563-70. (Pubitemid 26129582)
29. Madlambayan GJ, Rogers I, Kirouac DC, Yamanaka N, Mazurier F, Doedens M, et al. Dynamic changes in cellular and microenvironmental composition can be controlled to elicit in vitro human hematopoietic stem cell expansion. Exp Hematol. 2005;33:1229-39. (Pubitemid 41416972)
30. Timmins NE, Nielsen LK. Blood cell manufacture: current methods and future challenges. Trends Biotechnol. 2009;27: 415-22.
31. Bennaceur-Griscelli A, Pondarre C, Schiavon V, Vainchenker W, Coulombel L. Stromal cells retard the differentiation of CD34(+) CD38(low/neg) human primitive progenitors exposed to cytokines independent of their mitotic history. Blood. 2001;97:435-41. (Pubitemid 32060328)
32. Borge OJ, Ramsfjell V, Cui L, Jacobsen SEW. Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34(+)CD38(-) bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. Blood. 1997;90:2282-92. (Pubitemid 27392712)
33. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin- 3. Blood. 1996;88:429-36. (Pubitemid 26240373)
34. Piacibello W, Sanavio F, Garetto L, Severino A, Dane A, Gammaitoni L, et al. Differential growth factor requirement of primitive cord blood hematopoietic stem cell for selfrenewal and amplification vs proliferation and differentiation. Leukemia. 1998;12:718-27. (Pubitemid 28220825)
35. Gothot A, van der Loo JCM, Clapp DW, Srour EF. Cell cyclerelated changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic severe combined immune-deficient mice. Blood. 1998;92:2641-9. (Pubitemid 28469074)
36. Schiedlmeier B, Kuhlcke K, Eckert HG, Baum C, Zeller WJ, Fruehauf S. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood. 2000;95:1237-48. (Pubitemid 30099832)
37. Murray LJ, Young JC, Osborne LJ, Luens KM, Scollay R, Hill BL. Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34(+) cells and recruit primitive CD34(+)Thy-1(+) cells into rapid division. Exp Hematol. 1999;27:1019-28. (Pubitemid 29275390)
38. Lill MC, Lynch M, Fraser JK, Chung GY, Schiller G, Glaspy JA, et al. Production of functional myeloid cells from CD34- selected hematopoietic progenitor cells using a clinically relevant ex-vivo expansion system. Stem Cells. 1994;12: 626-37. (Pubitemid 24361712)
39. Scheding S, Meister B, Buhring HJ, Baum CM, McKearn JP, Bock T, et al. Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells. Exp Hematol. 2000;28:460-70. (Pubitemid 30214158)
40. Grotendorst GR, Smale G, Pencev D. Production of transforming growth-factor beta by human peripheral-blood monocytes and neutrophils. J Cell Physiol. 1989;140:396-402. (Pubitemid 19186005)
41. Mayani H, Little MT, Dragowska W, Thornbury G, Lansdorp PM. Differential-effects of the hematopoietic inhibi tors MIP- 1-alpha, TGF-beta, and TNF-alpha on cytokine-induced proliferation of subpopulations of CD34(+) cells puri fied from cord-blood and fetal liver. Exp Hematol. 1995;23: 422-7.
42. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood. 1998;92:2338-44. (Pubitemid 28452975)
43. Yang L, Dybedal I, Bryder D, Nilsson L, Sitnicka E, Sasaki Y, et al. IFN- ã negatively modulates self-renewal of repopulating human hemopoietic stem cells. J Immunol. 2005;174: 752-7. (Pubitemid 40094269)
44. Huang CH, Chen PM, Lu TC, Kung WM, Chiou TJ, Yang MH, et al. Purified recombinant TAT-HOXB4 expands CD34+ umbilical cord blood and peripheral blood progenitor cells ex vivo. Tissue Eng Part C Methods. 2009;16(3):487-496.
45. Amsellem S, Pflumio F, Bardinet D, Izac B, Charneau P, Romeo PH, et al. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat Med. 2003;9:1423-7. (Pubitemid 37466194)
46. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16:232-6.
47. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood. 1992;80:1405-12.
48. Makino S, Haylock DN, Dowse T, Trimboli S, Niutta S, To LB, et al. Ex vivo culture of peripheral blood CD34+ cells: effects of hematopoietic growth factors on production of neutrophilic precursors. J Hematother. 1997;6:475-89.
49. Lazzari L, Lucchi S, Rebulla P, Porretti L, Puglisi G, Lecchi L, et al. Long-term expansion and maintenance of cord blood haematopoietic stem cells using thrombopoietin, Flt3-ligand, interleukin (IL)-6 and IL-11 in a serum-free and stroma-free culture system. Br J Haematol. 2001;112:397-404. (Pubitemid 32183486)
50. Kohler T, Plettig R, Wetzstein W, Schaffer B, Ordemann R, Nagels HO, et al. Defining optimum conditions for the ex vivo expansion of human umbilical cord blood cells. Influences of progenitor enrichment, interference with feeder layers, earlyacting cytokines and agitation of culture vessels. Stem Cells. 1999;17:19-24. (Pubitemid 29063685)
51. Capmany G, Querol S, Cancelas J, Garcia J. Short-term, serum-free, static culture of cord blood-derived CD34+ cells: effects of FLT3-L and MIP-1alpha on in vitro expansion of hematopoietic progenitor cells. Haematologica. 1999;84: 675-82. (Pubitemid 29424401)
52. Brandt J, Srour EF, van Besien K, Briddell RA, Hoffman R. Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow. J Clin Invest. 1990;86:932-41. (Pubitemid 20327386)
53. Flores-Guzman P, Gutierrez-Rodriguez M, Mayani H. In vitro proliferation, expansion, and differentiation of a CD34+ cellenriched hematopoietic cell population from human umbilical cord blood in response to recombinant cytokines. Arch Med Res. 2002;33:107-14. (Pubitemid 34218942)
54. Yao C-L, Chu IM, Hsieh T-B, Hwang S-M. A systematic strategy to optimize ex vivo expansion medium for human hematopoietic stem cells derived from umbilical cord blood mononuclear cells. Exp Hematol. 2004;32:720-7. (Pubitemid 39092737)
55. Hino M, Suzuki K, Yamane T, Sakai N, Kubota H, Koh KR, et al. Ex vivo expansion of mature human neutrophils with normal functions from purified peripheral blood CD34+ haematopoietic progenitor cells. Br J Haematol. 2000;109:314-21. (Pubitemid 30350710)
56. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of Fk-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc. 1987;19:4-8. (Pubitemid 17157071)
57. Koenig JM, Matharoo N, Stegner JJ, Schowengerdt JKO. Tacrolimus: in vitro effects on myelopoiesis, apoptosis, and CD11b expression. J Heart Lung Transplant. 2005;24:1332-6. (Pubitemid 41247818)
58. Hirao A, Kawano Y, Takaue Y. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis. Blood. 1993;81:1179-83. (Pubitemid 23067353)
59. LaIuppa JA, Papoutsakis ET, Miller WM. Oxygen tension alters the effects of cytokines on the megakaryocyte, erythrocyte, and granulocyte lineages. Exp Hematol. 1998;26:835-43. (Pubitemid 28350754)
60. Hevehan DL, Wenning LA, Papoutsakis ET, Miller WM. A dynamic model of ex vivo granulopoiesis: effects of oxygen tension, pH, and IL-3. Exp Hematol. 2000;28(9):1016-28.
61. Hevehan DL, Papoutsakis ET, Miller WM. Physiologically significant effects of pH and oxygen tension on granulopoiesis. Exp Hemat. 2000;28:267-75. (Pubitemid 30137994)
62. Koller MR, Bender JG, Papoutsakis ET, Miller WM. Effects of synergistic cytokine combinations, low oxygen, and irradiated stroma on the expansion of human cord blood progenitors. Blood. 1992;80:403-11.
63. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res. 2005;65: 2537-41. (Pubitemid 40490047)
64. Seet L-F, Teng E, Lai Y-S, Laning J, Kraus M, Wnendt S, et al. Valproic acid enhances the engraftability of human umbilical cord blood hematopoietic stem cells expanded under serum-free conditions. Eur J Haematol. 2009;82: 124-32.